Cargando…

Association between the ERCC1 polymorphism and platinum-based chemotherapy effectiveness in ovarian cancer: a meta-analysis

BACKGROUND: Ovarian cancer is a prominent public health problem which affects people all around the world. Platinum-based chemotherapy is a common treatment for ovarian cancer, however, the effectiveness of chemotherapy varies from patient to patient. The excision repair cross complementation group...

Descripción completa

Detalles Bibliográficos
Autores principales:	Tang, Ning, Lyu, Dan, Zhang, Yan, Liu, Haiping
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	BioMed Central 2017
Materias:	Research Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5474010/ https://www.ncbi.nlm.nih.gov/pubmed/28623887 http://dx.doi.org/10.1186/s12905-017-0393-z

Ejemplares similares

Chinese C allele carriers of the ERCC5 rs1047768 polymorphism are more sensitive to platinum-based chemotherapy: a meta-analysis
por: Xu, Meizhen, et al.
Publicado: (2017)

Effect of ERCC1 polymorphisms on the response to platinum-based chemotherapy: A systematic review and meta-analysis based on Asian population
por: Wu, Xiaoqing, et al.
Publicado: (2023)

Study of the Relationship between ERCC1 Polymorphisms and Response to Platinum-based Chemotherapy in Iranian Patients with Colorectal and Gastric Cancers
por: Abyarghamsari, Mahdiye, et al.
Publicado: (2019)

ERCC1 polymorphisms as prognostic markers in T4 breast cancer patients treated with platinum-based chemotherapy
por: Palomba, Grazia, et al.
Publicado: (2014)

ERCC1, XRCC1, and GSTP1 Polymorphisms and Treatment Outcomes of Advanced Epithelial Ovarian Cancer Patients Treated with Platinum-based Chemotherapy
por: Liblab, Salisa, et al.
Publicado: (2020)

ERCC1 rs11615 polymorphism and chemosensitivity to platinum drugs in patients with ovarian cancer: a systematic review and meta-analysis
por: Zhang, Yuqiang, et al.
Publicado: (2021)

Prevalence of CTR1 and ERCC1 Polymorphisms and Response of Biliary Tract Cancer to Gemcitabine-Platinum Chemotherapy
por: Pongmaneratanakul, Skolchart, et al.
Publicado: (2017)

A common polymorphism in the 5′ UTR of ERCC5 creates an upstream ORF that confers resistance to platinum-based chemotherapy
por: Somers, Joanna, et al.
Publicado: (2015)

Association between common polymorphisms in ERCC gene and prognosis of osteosarcoma in patients treated with chemotherapy: a meta-analysis
por: Li, Chunpu, et al.
Publicado: (2018)

Genetic polymorphisms of ERCC-1 and ERCC-2 are not prognostic markers in osteosarcoma patients with chemotherapy: A meta-analysis in Chinese population
por: Liu, Dabiao, et al.
Publicado: (2018)

Genetic polymorphisms in ERCC1 and ERCC2 genes are associated with response to chemotherapy in osteosarcoma patients among Chinese population: a meta-analysis
por: Zhang, Haiguang, et al.
Publicado: (2017)

The expression of ERCC1 and BRCA1 predicts prognosis of platinum-based chemotherapy in urothelial cancer
por: Song, Wenhui, et al.
Publicado: (2016)

High ERCC1 expression is associated with platinum-resistance, but not survival in patients with epithelial ovarian cancer
por: Du, Pei, et al.
Publicado: (2016)

Association between the ERCC1 rs11615 polymorphism and clinical outcomes of oxaliplatin-based chemotherapies in gastrointestinal cancer: a meta-analysis
por: Ma, Shou-Cheng, et al.
Publicado: (2015)

Meta-Analysis of ERCC1 Protein Expression and Platinum Chemosensitivity in Non-Small-Cell Lung Cancer
por: Li, Guoping, et al.
Publicado: (2020)

ERCC1 Expression in Metastatic Triple Negative Breast Cancer Patients Treated with Platinum-Based Chemotherapy
por: Baiomy, Mohamed Ali EL, et al.
Publicado: (2017)

A Significant Statistical Advancement on the Predictive Values of ERCC1 Polymorphisms for Clinical Outcomes of Platinum-Based Chemotherapy in Non-Small Cell Lung Cancer: An Updated Meta-Analysis
por: Han, Yali, et al.
Publicado: (2016)

A miR‐15a related polymorphism affects NSCLC prognosis via altering ERCC1 repair to platinum‐based chemotherapy
por: Xue, Ping, et al.
Publicado: (2022)

Effect of the ERCC1 (C118T) Polymorphism on Treatment Response in Advanced Non-Small Cell Lung Cancer Patients Undergoing Platinum-Based Chemotherapy
por: Kaewbubpa, Walennee, et al.
Publicado: (2016)

Polymorphisms in ERCC2 and ERCC5 and Risk of Prostate Cancer: A Meta-Analysis and Systematic Review
por: Liu, Yi, et al.
Publicado: (2018)

Association between the ERCC5 Asp1104His Polymorphism and Cancer Risk: A Meta-Analysis
por: Zhu, Mei-Ling, et al.
Publicado: (2012)

Associations between XRCC2 rs3218536 and ERCC2 rs13181 polymorphisms and ovarian cancer
por: Zhang, Wei, et al.
Publicado: (2016)

Polymorphisms in ERCC4 and ERCC5 and risk of cancers: Systematic research synopsis, meta-analysis, and epidemiological evidence
por: Zuo, Chunjian, et al.
Publicado: (2022)

The Association of ERCC1 and ERCC5 Polymorphisms with Lung Cancer Risk in Han Chinese
por: Lan, Xueling, et al.
Publicado: (2022)

Effect of XPC polymorphisms on the response to platinum-based chemotherapy: a meta-analysis
por: Xie, Chenyao, et al.
Publicado: (2019)

DNA repair gene ERCC2 polymorphisms and associations with breast and ovarian cancer risk
por: Bernard-Gallon, Dominique, et al.
Publicado: (2008)

Association between the XRCC1 polymorphisms and clinical outcomes of advanced NSCLC treated with platinum-based chemotherapy: a meta-analysis based on the PRISMA statement
por: Li, Dan-Juan, et al.
Publicado: (2017)

Association of ERCC1 C8092A and ERCC2 Lys751Gln Polymorphisms with the Risk of Glioma: A Meta-Analysis
por: Xin, Yu, et al.
Publicado: (2014)

ERCC1-expressing circulating tumor cells as a potential diagnostic tool for monitoring response to platinum-based chemotherapy and for predicting post-therapeutic outcome of ovarian cancer
por: Chebouti, Issam, et al.
Publicado: (2016)

Association between common polymorphisms in ERCC gene and glioma risk: A meta-analysis of 15 studies
por: Qian, Tengda, et al.
Publicado: (2017)

Polymorphisms in ERCC1, GSTs, TS and MTHFR predict clinical outcomes of gastric cancer patients treated with platinum/5-Fu-based chemotherapy: a systematic review
por: Wang, Zhen, et al.
Publicado: (2012)

Association of ERCC gene polymorphism with osteosarcoma risk
por: Wang, Guanliang, et al.
Publicado: (2020)

Prognostic Value of EGFR Mutation and ERCC1 in Patients with Non-Small Cell Lung Cancer Undergoing Platinum-Based Chemotherapy
por: Yamashita, Fumie, et al.
Publicado: (2013)

Association of ERCC1 and ERCC2 polymorphisms with colorectal cancer risk in a Chinese population
por: Ni, Min, et al.
Publicado: (2014)

Association of ERCC1 rs3212986 & ERCC2 rs13181 polymorphisms with the risk of glioma
por: Cui, Qing-ke, et al.
Publicado: (2014)

Meta-analysis showing that ERCC1 polymorphism is predictive of osteosarcoma prognosis
por: Liu, Xueyong, et al.
Publicado: (2017)

ERCC1 and XRCC1 but not XPA single nucleotide polymorphisms correlate with response to chemotherapy in endometrial carcinoma
por: Chen, Liang, et al.
Publicado: (2016)

Association between the ERCC2 Asp312Asn polymorphism and risk of cancer
por: Xiao, Feifan, et al.
Publicado: (2017)

ERCC1_202 Is A Prognostic Biomarker in Advanced Stage Non-Small Cell Lung Cancer Patients Treated with Platinum-Based Chemotherapy
por: Wang, Xiyong, et al.
Publicado: (2017)

Association between polymorphisms in ERCC2 gene and oral cancer risk: evidence from a meta-analysis
por: Zhang, Enjiao, et al.
Publicado: (2013)

Cannot write session to /tmp/vufind_sessions/sess_tojkjkdumrbc57smc7fgp7f2rb